AtriCure says it “welcomes” competition and that competition “is a great thing.” The company says it is at “such an early stage” within cardiac surgery and “welcomes a competitor that is a good competitor.” Comments taken from the Piper Sandler Healthcare Conference.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ATRC:
- Medtronic launch could create an overhang on AtriCure, says Needham
- Medtronic launches Penditure Left Atrial Appendage Exclusion System in U.S.
- AtriCure price target lowered to $49 from $68 at Needham
- AtriCure price target lowered to $45 from $79 at Canaccord
- AtriCure sees FY23 EPS (76c) to (74c) , consensus (92c)